Loading stock data…
FMS
$24.59+0.15 (+0.61%)
Market ClosedLast close Jul 24
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fresenius Medical Care AG in the Healthcare sector is trading at $24.59 with a market capitalization of $12.7B. Wall Street consensus targets $25.58 (7 analysts), implying a +4.0% move over the next 12 months. The stock is currently 11% below its 52-week high of $27.64, remaining 8.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.61B↓ | $5.07B↑ | $4.88B↑ | $4.79B↓ | $4.88B |
| Gross Profit | $1.18B↓ | $1.39B↑ | $1.24B↑ | $1.21B↑ | $1.18B |
| Operating Income | $375.56M↓ | $548.98M↑ | $501.72M↑ | $394.40M↑ | $381.73M |
| Net Income | $117.53M↓ | $327.08M↑ | $274.80M↑ | $225.27M↑ | $151.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a ne...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.13%
Volume
Today's trading volume
566,903
Recent News
Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary
Moby summary of Quest Diagnostics Incorporated's Q2 2026 earnings call
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.
Quest Diagnostics Q2 Earnings Call Highlights
Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to...
DaVita Stock Benefits From Strengthening Kidney Care Delivery
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.